Immuneering said it will present two preclinical posters on atebimetinib combination strategies at ENA2026 in Barcelona on Nov. 18-19. The data will cover pancr

Immuneering said it will present two preclinical posters on atebimetinib combination strategies at ENA2026 in Barcelona on Nov. 18-19. The data will cover pancreatic and anaplastic thyroid cancers, following earlier pancreatic model results showing lower tumor volume.